Related Experiment Video
Updated: Sep 6, 2025

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Apelin is expressed throughout the human kidney, is elevated in chronic kidney disease & associates independently
Duuamene Nyimanu1, Fiona A Chapman2,3, Peter J Gallacher2
1Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
Insights
Plasma apelin is elevated in chronic kidney disease (CKD) and may indicate a higher risk of kidney function decline. The apelin system is present in healthy kidneys, warranting further research into apelin agonism as a CKD therapy.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Endocrinology
Background:
- Cardiovascular disease (CVD) is a major complication of chronic kidney disease (CKD).
- The apelin system presents a potential therapeutic target for CVD, but its role in CKD remains under-explored.
- Limited data exist on the expression and function of the apelin system in the context of CKD.
Purpose of the Study:
- To investigate the expression of the apelin system in healthy human kidneys.
- To examine the levels of apelin and Elabela/Toddler (ELA) in patients with CKD.
- To explore the association between apelin, ELA, and cardiovascular health in CKD patients.
Main Methods:
- Autoradiography, immunohistochemistry, and ELISA were used to assess apelin system expression in kidney tissue.
- Plasma levels of apelin and ELA were measured in 128 CKD patients and 27 healthy controls.
- Cardiovascular parameters including blood pressure, arterial stiffness, and endothelial function were assessed over a 5-year follow-up period.
Main Results:
- The apelin system is expressed throughout the nephron in healthy human kidneys.
- Plasma apelin concentrations were significantly higher in women than men and increased with declining glomerular filtration rate and rising albuminuria in CKD patients.
- Elevated plasma apelin and ELA were associated with vascular dysfunction, and plasma apelin independently predicted a 50% decline in glomerular filtration rate over 5 years.
Conclusions:
- This study demonstrates the expression of the apelin system in healthy human kidneys.
- Elevated plasma apelin levels in CKD patients may serve as a potential biomarker for the risk of kidney function decline.
- Further clinical investigations into the therapeutic potential of apelin agonism for CKD are warranted.
Aims:
Chronic kidney disease (CKD) is common and cardiovascular disease (CVD) is its commonest complication. The apelin system is a potential therapeutic target for CVD but data relating to apelin in CKD are limited. We examined expression of the apelin system in human kidney, and investigated apelin and Elabela/Toddler (ELA), the endogenous ligands for the apelin receptor, in patients with CKD.
Methods:
Using autoradiography, immunohistochemistry and enzyme-linked immunosorbent assay, we assessed expression of apelin, ELA and the apelin receptor in healthy human kidney, and measured plasma apelin and ELA in 155 subjects (128 patients with CKD, 27 matched controls) followed up for 5 years. Cardiovascular assessments included blood pressure, arterial stiffness (pulse wave velocity) and brachial artery flow-mediated dilation. Surrogate markers of endothelial function (plasma asymmetric dimethylarginine and endothelin-1) and inflammation (C-reactive protein and interleukin-6) were measured.
Results:
The apelin system was expressed in healthy human kidney, throughout the nephron. Plasma apelin concentrations were 60% higher in women than men (6.48 [3.62-9.89] vs. 3.95 [2.02-5.85] pg/mL; P < .0001), and increased as glomerular filtration rate declined (R = -0.41, P < .0001), and albuminuria rose (R = 0.52, P < .0001). Plasma apelin and ELA were associated with vascular dysfunction. Plasma apelin associated independently with a 50% decline in glomerular filtration rate at 5 years.
Conclusion:
We show for the first time that the apelin system is expressed in healthy human kidney. Plasma apelin is elevated in CKD and may be a potential biomarker of risk of decline in kidney function. Clinical studies exploring the therapeutic potential of apelin agonism in CKD are warranted.
More Related Videos
11:47Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
Published on: March 4, 2022
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Related Concept Videos
Chronic Kidney Disease I: Introduction
Nephrons
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention